Spots Global Cancer Trial Database for relapsed aml
Every month we try and update this database with for relapsed aml cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia | NCT05226468 | Advanced Solid ... Relapsed AML Refractory AML | NEI-01 | 18 Years - | New Epsilon Innovation Limited | |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | NCT00317642 | Acute Myelogeno... | clofarabine (IV... placebo cytarabine | 55 Years - | Sanofi | |
| Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML | NCT02891278 | Acute Myeloid L... | Sertraline Cytosine arabin... allogeneic stem... | 18 Years - 70 Years | Columbia University | |
| Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia | NCT02631252 | Leukemia, Acute... | Hydroxychloroqu... Mitoxantrone Etoposide | 18 Years - 80 Years | University of Pittsburgh | |
| Bisantrene for Relapsed /Refractory AML | NCT03820908 | Acute Myelogeno... Allogeneic Stem... | Bisantrene | 18 Years - | Sheba Medical Center | |
| Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | NCT02743611 | Acute Myeloid L... Myelodysplastic... Uveal Melanoma | BPX-701 Rimiducid | 18 Years - | Bellicum Pharmaceuticals | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies | NCT01009931 | Leukemia | 12-O-tetradecan... Dexamethasone Choline magnesi... | 18 Years - | Rutgers, The State University of New Jersey | |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | NCT00317642 | Acute Myelogeno... | clofarabine (IV... placebo cytarabine | 55 Years - | Sanofi | |
| Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia | NCT01158885 | Minimal Residua... Leukemia, Lymph... Leukemia, Myelo... | Clofarabine Cytarabine intr... Methotrexate Intrathecal (IT... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | NCT01130662 | Acute Myeloid L... | combination the... | 18 Years - | University of Kansas Medical Center | |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03347994 | Acute Myeloid L... | Minnelide | 18 Years - | University of Miami | |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | NCT03616470 | Acute Myeloid L... | Uproleselan Placebo | 18 Years - 75 Years | GlycoMimetics Incorporated | |
| Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | NCT03560908 | Relapsed AML T(8;21) C-KIT Mutation | Dasatinib | - | Institute of Hematology & Blood Diseases Hospital, China | |
| T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) | NCT00939653 | Relapsed Acute ... | Clofarabine Etoposide Cyclophosphamid... Filgrastim Cytarabine | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | NCT03516760 | Acute Myeloid L... Relapsed AML Refractory AML | GEM333 | 18 Years - | AvenCell Europe GmbH | |
| Phase 1 Study of Quizartinib | NCT02675478 | Relapsed AML Refractory AML | AC220 | 20 Years - | Daiichi Sankyo | |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | NCT02074839 | Relapsed or Ref... Untreated AML Other IDH1-muta... Myelodysplastic... | AG-120 | 18 Years - | Servier | |
| Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | NCT03616470 | Acute Myeloid L... | Uproleselan Placebo | 18 Years - 75 Years | GlycoMimetics Incorporated | |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia | NCT01037556 | Acute Myelogeno... Acute Lymphocyt... | PR104 | 18 Years - | Proacta, Incorporated | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03347994 | Acute Myeloid L... | Minnelide | 18 Years - | University of Miami | |
| Alvocidib Biomarker-driven Phase 2 AML Study | NCT02520011 | Acute Myeloid L... | Alvocidib Cytarabine Mitoxantrone | 18 Years - 65 Years | Sumitomo Pharma America, Inc. | |
| Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia | NCT01130662 | Acute Myeloid L... | combination the... | 18 Years - | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
